Video: Perturb PBMC - Functional Proteomics of the PBMC Secretome

March 19, 2026
On Demand

Runtime: 8:33

Perturbation screens are reshaping drug discovery, turning observation into causal, data-driven insight.

Most rely on RNA or imaging readouts; affordable, yet poor proxies for functional protein activity. To interrogate function, you have to measure proteins. But the protein layer has always been hard to access at scale, expensive, slow, and complex. At Nomic we’ve been changing that—delivering proteome-wide functional insights at genomic costs.

Hosted by Nathaniel Robichaud, PhD, Partnerships Lead at Nomic, this short video explores findings from our large-scale PBMC screen and their implications for multiple sclerosis, and details how you can explore the dataset yourself to draw your own conclusions.

Video: Perturb PBMC - Functional Proteomics of the PBMC Secretome

On Demand
March 19, 2026

Subscribe to Updates

Get the latest insights and updates delivered straight to your inbox weekly.

Runtime: 8:33

Perturbation screens are reshaping drug discovery, turning observation into causal, data-driven insight.

Most rely on RNA or imaging readouts; affordable, yet poor proxies for functional protein activity. To interrogate function, you have to measure proteins. But the protein layer has always been hard to access at scale, expensive, slow, and complex. At Nomic we’ve been changing that—delivering proteome-wide functional insights at genomic costs.

Hosted by Nathaniel Robichaud, PhD, Partnerships Lead at Nomic, this short video explores findings from our large-scale PBMC screen and their implications for multiple sclerosis, and details how you can explore the dataset yourself to draw your own conclusions.

Video: Perturb PBMC - Functional Proteomics of the PBMC Secretome

On Demand
March 19, 2026

Read the full publication

Watch Now

Runtime: 8:33

Perturbation screens are reshaping drug discovery, turning observation into causal, data-driven insight.

Most rely on RNA or imaging readouts; affordable, yet poor proxies for functional protein activity. To interrogate function, you have to measure proteins. But the protein layer has always been hard to access at scale, expensive, slow, and complex. At Nomic we’ve been changing that—delivering proteome-wide functional insights at genomic costs.

Hosted by Nathaniel Robichaud, PhD, Partnerships Lead at Nomic, this short video explores findings from our large-scale PBMC screen and their implications for multiple sclerosis, and details how you can explore the dataset yourself to draw your own conclusions.

Video: Perturb PBMC - Functional Proteomics of the PBMC Secretome

On Demand
March 19, 2026

Runtime: 8:33

Perturbation screens are reshaping drug discovery, turning observation into causal, data-driven insight.

Most rely on RNA or imaging readouts; affordable, yet poor proxies for functional protein activity. To interrogate function, you have to measure proteins. But the protein layer has always been hard to access at scale, expensive, slow, and complex. At Nomic we’ve been changing that—delivering proteome-wide functional insights at genomic costs.

Hosted by Nathaniel Robichaud, PhD, Partnerships Lead at Nomic, this short video explores findings from our large-scale PBMC screen and their implications for multiple sclerosis, and details how you can explore the dataset yourself to draw your own conclusions.

Watch Video Now

Video: Perturb PBMC - Functional Proteomics of the PBMC Secretome

On Demand
March 19, 2026

Runtime: 8:33

Perturbation screens are reshaping drug discovery, turning observation into causal, data-driven insight.

Most rely on RNA or imaging readouts; affordable, yet poor proxies for functional protein activity. To interrogate function, you have to measure proteins. But the protein layer has always been hard to access at scale, expensive, slow, and complex. At Nomic we’ve been changing that—delivering proteome-wide functional insights at genomic costs.

Hosted by Nathaniel Robichaud, PhD, Partnerships Lead at Nomic, this short video explores findings from our large-scale PBMC screen and their implications for multiple sclerosis, and details how you can explore the dataset yourself to draw your own conclusions.

Download resource

Get the latest insights and updates delivered straight to your inbox weekly.

Video: Perturb PBMC - Functional Proteomics of the PBMC Secretome

On Demand
March 19, 2026

Get the latest insights and updates delivered straight to your inbox weekly.

Runtime: 8:33

Perturbation screens are reshaping drug discovery, turning observation into causal, data-driven insight.

Most rely on RNA or imaging readouts; affordable, yet poor proxies for functional protein activity. To interrogate function, you have to measure proteins. But the protein layer has always been hard to access at scale, expensive, slow, and complex. At Nomic we’ve been changing that—delivering proteome-wide functional insights at genomic costs.

Hosted by Nathaniel Robichaud, PhD, Partnerships Lead at Nomic, this short video explores findings from our large-scale PBMC screen and their implications for multiple sclerosis, and details how you can explore the dataset yourself to draw your own conclusions.